Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"November 04, 2026 3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . “
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Adults with obesity who underwent bariatric surgery exhibited lower risk for several cancers than those who did not have the surgery. The cancer-protective benefits persisted regardless of sex or age. Bariatric surgery can offer long-term cancer-protective effects for people with obesity regardless of their sex or age, findings of a population-based cohort study suggest. An analysis of registry data from nearly 800,000 people showed those who underwent the procedure exhibited an overall significantly lower risk for 10 obesity-related malignancies.
Data derived from\u00a0Radkiewicz C, et al. JAMA Surg. 2026;doi:10.1001\/jamasurg.2026.4798.
The magnitude of risk reduction remained consistent between younger and older adults, and analyses that focused on cancer types that affect both sexes showed comparable benefits for men and women. Cecilia Radkiewicz \u201cThe primary indication for bariatric surgery is weight loss in individuals with obesity, not cancer prevention. However, because these findings show the reduction in obesity-related cancer risk is similar among men and women, and across age groups, they strengthen the evidence that access to bariatric surgery should be equitable whenever it is clinically indicated,\u201d lead author Cecilia Radkiewicz, MD, PhD, medical oncologist and researcher in the department of molecular medicine and surgery at Karolinska Institutet in Stockholm, told Healio. A closer examination The CDC has linked obesity to 13 malignancies, which combined account for about 40% of all cancers diagnosed in the U.S. each year. Radkiewicz and colleagues aimed to clarify the association between bariatric surgery and incidence of 10 obesity-related malignancies: breast, colon, endometrial, kidney, liver, ovarian, pancreatic and rectal cancers; esophageal adenocarcinoma; and multiple myeloma. The researchers also assessed whether associations between bariatric surgery and obesity-related cancer risk varied between men and women, or by age at the time of surgery. \u201cPrevious studies have shown that bariatric surgery reduces the risk of obesity-related malignancies overall; however, that association has appeared to be strongest among women and may be partly explained by hormone-driven cancers \u2014 like breast cancer, ovarian cancer or endometrial cancer \u2014 that primarily affect women,\u201d Radkiewicz said. \u201cWe wanted to examine more closely whether there were differences between men and women by focusing on cancers that affect both sexes. We also hypothesized that the effect of bariatric surgery would be stronger among individuals who underwent surgery at a younger age, given the long latency between carcinogenic exposures and cancer development.\u201d The researchers used the Nordic Obesity Surgery Cohort (NordOSCo) \u2014 a large, multinational registry \u2014 to identify 784,105 people (73% women) aged 18 to 59 years in Denmark, Finland and Sweden. All individuals had a record of obesity or underwent bariatric surgery between 1992 and 2023. Approximately 12.7% (n = 99,614) underwent bariatric surgery during follow-up. Incidence of obesity-related cancers served as the primary outcome, with analyses adjusted for comorbidities such as diabetes, hypertension and COPD. Consistent findings Median follow-up ranged from 6.4 years to 9.5 years. Bariatric surgery appeared associated with a nearly 20% lower risk for any obesity-related cancer in the overall cohort (adjusted incidence rate ratio [aIRR] = 0.81; 95% CI, 0.77-0.85). The magnitude of benefit remained consistent between individuals aged 18 to 39 years (aIRR = 0.8; 95% CI, 0.72-0.88) at the time of surgery and those aged 40 to 59 (aIRR = 0.81; 95% CI, 0.78-0.86). When researchers restricted analyses to cancers that affect both sexes, results showed similar risk reductions among men and women. Results showed the strongest inverse associations between bariatric surgery and incidence for liver cancer (aIRR = 0.49; 95% CI, 0.34-0.7), endometrial cancer (aIRR = 0.51; 95% CI, 0.45-0.59) and ovarian cancer (aIRR = 0.73; 95% CI, 0.6-0.87). However, results showed what Radkiewicz described as a \u201csurprisingly\u201d elevated pancreatic cancer risk among individuals who underwent bariatric surgery, with the association most pronounced among younger adults (aIRR = 2.21; 95% CI, 1.44-3.39). \u201cAny potential underlying mechanisms remain unclear, and the observed association should be interpreted with caution, Radkiewicz said. \u201cThis finding needs to be replicated in other cohorts before any conclusions can be drawn.\u201d Long-term oncologic benefits The researchers acknowledged study limitations, including the potential for residual or unmeasured confounding due to its observational design and the possibility that follow-up may not have been sufficient to capture long-latency cancers. Investigators also lacked information about BMI \u2014 precluding adjustment for obesity severity \u2014 and potentially confounding lifestyle factors, such as smoking, diet, physical activity or alcohol consumption. However, the findings suggest that bariatric surgery confers long-term oncologic benefits to men and women regardless of age and underscore how effective obesity treatment can contribute to long-term health, researchers concluded. The researchers will continue to use the NordOSCo cohort, which is continuously updated and also includes data from Norway and Iceland, for additional research. The expanded cohort will further increase study power and facilitate investigations of a broad range of health outcomes related to obesity and bariatric surgery, including cancer risk, Radkiewicz said. For more information: Cecilia Radkiewicz, MD, PhD, can be reached at cecilia.radkiewicz@ki.se. Published by: Sources\/Disclosures Source:
Radkiewicz C, et al. JAMA Surg. 2026;doi:10.1001\/jamasurg.2026.4798. References:
Disclosures:
Nordic Cancer Union, Region Stockholm, Swedish Cancer Society and Swedish Society of Medicine supported the study. Radkiewicz reports an unrestricted research grant from Amgen, as well as advisory board roles with NeoGAP, Pierre Fabre and Takeda. The other authors report no relevant financial disclosures.
Ask a clinical question and tap into Healio AI’s knowledge base.
PubMed, enrolling\/recruiting trials, guidelines
Clinical Guidance, Healio CME, FDA news
Healio’s exclusive daily news coverage of clinical data
Learn more
Add topic to email alerts
Receive an<\/p>\n","protected":false},"author":1,"featured_media":4262,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4261","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/4261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4261"}],"version-history":[{"count":0,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/4261\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/media\/4262"}],"wp:attachment":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"hemonc](\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/hot.svg?la=en&h=24&w=141&hash=2F86D471C8514C0E334E329AA799E8B4\")
\n <\/div>\n<\/p><\/div>\n<\/p><\/div>\n